Article
BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Journal of surgical oncology - 1 Aug 2012
Teng Hao-Wei, Huang Yu-Chung, Lin Jen-Kou, Chen Wei-Shone, Lin Tzu-Chen, Jiang Jeng-Kai, Yen Chueh-Chuan, Li Anna Fen-Yau, Wang Hsei-Wei, Chang Shih-Ching, Lan Yuan-Tzu, Lin Chun-Chi, Wang Huann-Sheng, Yang Shung-Haur
Abstract excerpt
BACKGROUND AND OBJECTIVES: In metastatic colorectal cancer, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is a predictive biomarker for anti-epidermal growth factor receptor (EGFR) treatment and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) is a prognostic biomarker. We aimed to determine the impact of KRAS and BRAF mutation as determined from liver metastases specimens on overall survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
